uniQure followed the plan it had agreed with the FDA for its Huntington’s disease gene therapy. Then the agency changed its mind, and the stock fell 40%, then another 35%.
A company with one moonshot
Simply put, uniQure is a gene therapy company. It is not a pharma giant with thousands of drugs but a specialized lab with one moonshot: a bet on solving diseases at the genetic level, with a one-time treatment that could potentially fix the root cause of a disease forever.
Its current best bet is AMT-130, a gene therapy for Huntington’s disease, a fatal hereditary condition in which a mutated gene slowly destroys a person’s brain cells. No treatment is currently available, and AMT-130 aims to fill that gap.
AMT-130 is given once, injected directly into the brain (into the striatum, in uniQure’s own description), where it delivers a genetic silencer to suppress the toxic protein that the Huntington’s mutation produces. Phase 1/2 trial data showed a 75% reduction in disease progression three years after a single treatment. Those surprising results caused uniQure’s stock price to triple. For a disease with zero options that modify its course, AMT-130 was considered a potential breakthrough. The company was weeks away from filing for FDA approval.
An FDA in freefall
uniQure did not just get an unfavorable ruling. It got caught in the crossfire of a deeply unstable regulatory agency.
Heading into 2026, the FDA was mired in high-profile departures, feuds between top leaders, accusations of politicization and catastrophically low morale. The drug center had been led by five different people since January 2025 alone. The agency’s workforce was down over 1,300 net employees from the start of 2025, and it approved only 46 drugs that year, lower than every year in the past decade except 2022.
A major driver of the internal chaos was Vinay Prasad, a top deputy to Commissioner Marty Makary. Biotech companies openly don’t trust him and view him as anti-innovation. Biotech stocks soared when he was briefly ousted in mid-2025, then fell when he came back. Prasad has been accused of pushing at least seven top scientists out of the agency and causing others to self-censor.
This is the FDA that uniQure was trying to get approval from.
What happened to uniQure
uniQure had spent years working with the FDA, going through multiple meetings, reaching alignment on its statistical analysis plan and agreeing on the exact external control dataset to use as its comparator. Everything was set, with an approval set for Q1 2026.
Then, in November 2025, the FDA changed its mind, deeming the Phase 1/2 data based on an external control no longer adequate to support an approval application. CEO Matt Kapusta called it “a drastic change” from prior guidance. The stock fell 40%.
This happened even though the two parties had previously agreed on the exact protocols and statistical analyses. uniQure followed the rules the FDA gave it, and the FDA seemingly changed them without notice.
Around the same time, Commissioner Makary, without naming AMT-130 directly, publicly referenced an investigational brain therapy that the agency had been “pressured” to approve despite finding no clinical benefit to patients. The comment was widely understood to be about AMT-130.
By the final meeting in January 2026, the FDA was demanding a full prospective, randomized, double-blind, sham surgery-controlled Phase 3 study before any approval filing, effectively closing the door on a near-term approval. Shares fell another 35%. Google Finance shows the stock closing at $19.13 on May 1, down 44.21% over the past six months.
Insights and impact
uniQure’s situation is not an isolated incident. Critics argue the FDA is now “replacing standards of safety and efficacy with fear and favor,” and that the resulting unpredictability is “undermining the ability of innovators to bring medicines to market with confidence.” Analysts at RBC Capital Markets warned that “continued shifts in leadership and unpredictability remain a potential headwind” for the entire sector.
For uniQure, the path forward is now uncertain. The company is pursuing approval in the UK and EU, where regulators appear more open to the existing data. It is updating its statistical plan to include a four-year data readout expected in late 2026, hoping stronger long-term numbers might reopen dialogue in the U.S. It is also requesting a meeting with the FDA to discuss trial design options.
The larger question is not just about uniQure but about what happens to drug development when the rulebook can change mid-game. Small biotech companies bet years of work and hundreds of millions of dollars on a regulatory framework they were told was agreed upon. An erratic FDA does not just hurt one company. It threatens America’s position in biotech entirely, as companies begin considering moving their regulatory filings and funding requests to more predictable environments.
Patients with Huntington’s disease, a progressive and fatal condition, are the ones left waiting.